

A common polymorphism acts as an intragenic modifier

Nature Genetics

25, 47-54

DOI: [10.1038/75586](https://doi.org/10.1038/75586)

Citation Report

#	ARTICLE	IF	CITATIONS
1	p53 and p73: seeing double?. Nature Genetics, 2000, 26, 391-392.	9.4	13
2	Dominant modifier DFNM1 suppresses recessive deafness DFNB26. Nature Genetics, 2000, 26, 431-434.	9.4	130
3	Role of the p53-homologue p73 in E2F1-induced apoptosis. Nature Genetics, 2000, 26, 464-469.	9.4	319
4	p63 and p73: p53 mimics, menaces and more. Nature Reviews Molecular Cell Biology, 2000, 1, 199-207.	16.1	443
5	From p63 to p53 across p73. FEBS Letters, 2001, 490, 163-170.	1.3	79
6	Role of the newer p53 family proteins in malignancy. , 2001, 6, 17-29.		67
7	E2F-1 induced apoptosis. , 2001, 6, 173-182.		121
8	p73 in apoptosis. , 2001, 6, 447-452.		57
9	Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene, 2001, 20, 320-328.	2.6	145
10	p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene, 2001, 20, 769-774.	2.6	86
11	The role of tetramerization in p53 function. Oncogene, 2001, 20, 2611-2617.	2.6	232
12	p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene, 2001, 20, 4050-4057.	2.6	44
13	Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene, 2001, 20, 5111-5117.	2.6	61
14	The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene, 2001, 20, 4891-4898.	2.6	17
15	Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Reviews Cancer, 2001, 1, 233-239.	12.8	587
16	p53, p63 and p73 "solos, alliances and feuds among family members. Biochimica Et Biophysica Acta: Reviews on Cancer, 2001, 1552, 47-59.	3.3	65
17	p73 is highly expressed in myoepithelial cells and in carcinomas with metaplasia. International Journal of Oncology, 2001, 19, 271-6.	1.4	9
18	p73 is over-expressed in vulval cancer principally as the $\Delta 127$ isoform. British Journal of Cancer, 2001, 85, 1551-1556.	2.9	45

#	ARTICLE	IF	CITATIONS
19	Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2001, 276, 15164-15173.	1.6	368
20	The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. <i>Molecular and Cellular Biology</i> , 2001, 21, 8461-8470.	1.1	117
21	Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. <i>Carcinogenesis</i> , 2001, 22, 515-517.	1.3	67
22	Human T-cell Leukemia Virus Type I Tax Repression of p73 ^{Δ2} Is Mediated through Competition for the C/H1 Domain of CBP. <i>Journal of Biological Chemistry</i> , 2001, 276, 15720-15727.	1.6	49
23	A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain. <i>Molecular and Cellular Biology</i> , 2001, 21, 1874-1887.	1.1	434
24	Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. <i>Carcinogenesis</i> , 2001, 22, 1727-1731.	1.3	70
25	ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. <i>Journal of Experimental Medicine</i> , 2002, 196, 765-780.	4.2	309
26	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. <i>Journal of Biological Chemistry</i> , 2002, 277, 18817-18826.	1.6	203
27	Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14849-14854.	3.3	195
28	Induction of p57KIP2 expression by p73 ^{Δ2} . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3529-3534.	3.3	91
29	Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. <i>Journal of Biological Chemistry</i> , 2002, 277, 43359-43368.	1.6	125
30	p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. <i>Journal of the National Cancer Institute</i> , 2002, 94, 681-690.	3.0	214
31	Autoinhibitory Regulation of p73 by ΔNp73 To Modulate Cell Survival and Death through a p73-Specific Target Element within the ΔNp73 Promoter. <i>Molecular and Cellular Biology</i> , 2002, 22, 2575-2585.	1.1	172
32	HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes. <i>International Journal of Oncology</i> , 2002, 21, 561.	1.4	5
33	Physical Interaction of p73 with c-Myc and MM1, a c-Myc-binding Protein, and Modulation of the p73 Function. <i>Journal of Biological Chemistry</i> , 2002, 277, 15113-15123.	1.6	64
34	Transactivation-deficient ΔTA-p73 Inhibits p53 by Direct Competition for DNA Binding. <i>Journal of Biological Chemistry</i> , 2002, 277, 14177-14185.	1.6	155
35	p53 regulation of DNA excision repair pathways. <i>Mutagenesis</i> , 2002, 17, 149-156.	1.0	143
36	Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. <i>International Review of Cytology</i> , 2002, 219, 157-198.	6.2	8

#	ARTICLE	IF	CITATIONS
37	Human papillomaviruses and non-melanoma skin cancer. <i>Current Opinion in Infectious Diseases</i> , 2002, 15, 101-114.	1.3	159
38	Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. <i>Experimental Cell Research</i> , 2002, 275, 122-131.	1.2	18
39	Disruption of Oncogene/Tumor Suppressor Networks During Human Carcinogenesis. <i>Cancer Investigation</i> , 2002, 20, 71-81.	0.6	34
40	p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 539-541.	1.0	38
41	Apoptosis: biochemical aspects and clinical implications. <i>Clinica Chimica Acta</i> , 2002, 326, 27-45.	0.5	200
42	A role for p53 in the frequency and mechanism of mutation. <i>Mutation Research - Reviews in Mutation Research</i> , 2002, 511, 45-62.	2.4	73
43	p53 codon 72 polymorphism and its association with bladder cancer. <i>Cancer Letters</i> , 2002, 179, 175-183.	3.2	120
44	No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. <i>Cancer Letters</i> , 2002, 181, 81-85.	3.2	86
45	P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. <i>Cancer Letters</i> , 2002, 183, 123-130.	3.2	94
46	What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. <i>Experimental Gerontology</i> , 2002, 37, 1263-1271.	1.2	67
47	Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (oscc) patients of Eastern India. <i>International Journal of Cancer</i> , 2002, 97, 649-653.	2.3	128
48	Relationship Between p53 Codon 72 Polymorphism and Susceptibility to Sunburn and Skin Cancer. <i>Journal of Investigative Dermatology</i> , 2002, 119, 84-90.	0.3	83
49	TP53 Polymorphism of Exon 4 at Codon 72 in Cutaneous Squamous Cell Carcinoma and Benign Epithelial Lesions of Renal Transplant Recipients and Immunocompetent Individuals: Lack of Correlation with Human Papillomavirus Status11This work was presented in part at the 19th International Papillomavirus Conference in Florianopolis, Brazil, September 1â€“7, 2001.. <i>Journal of Investigative Dermatology</i> , 2002, 118, 1026-1031.	0.3	29
50	P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 383-388.	1.2	36
51	Role of p73 in malignancy: tumor suppressor or oncogene?. <i>Cell Death and Differentiation</i> , 2002, 9, 237-245.	5.0	147
52	Hetero-oligomerization does not compromise â€“gain of functionâ€™ of tumor-derived p53 mutants. <i>Oncogene</i> , 2002, 21, 176-189.	2.6	31
53	The p53 network in lung carcinogenesis. <i>Oncogene</i> , 2002, 21, 6898-6907.	2.6	130
54	p73: Friend or foe in tumorigenesis. <i>Nature Reviews Cancer</i> , 2002, 2, 605-615.	12.8	526

#	ARTICLE	IF	CITATIONS
55	Live or let die: the cell's response to p53. <i>Nature Reviews Cancer</i> , 2002, 2, 594-604.	12.8	2,906
56	Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. <i>British Journal of Cancer</i> , 2002, 87, 1013-1018.	2.9	85
57	HPV16/18 Prevalence in Cervical Lesions/Cancers and p53 Genotypes in Cervical Cancer Patients from India. <i>Gynecologic Oncology</i> , 2002, 86, 157-162.	0.6	55
58	Studying genotype-phenotype relationships: cardiovascular disease as an example. <i>Journal of Molecular Medicine</i> , 2002, 80, 282-289.	1.7	11
59	p73, the "Assistant" Guardian of the Genome?. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 9-15.	1.8	35
60	Association of p53 codon arg72pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. <i>Breast Cancer</i> , 2003, 10, 307-311.	1.3	86
61	A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. <i>Journal of Biomedical Science</i> , 2003, 10, 430-435.	2.6	57
62	Chemosensitivity linked to p73 function. <i>Cancer Cell</i> , 2003, 3, 403-410.	7.7	394
63	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. <i>Cancer Cell</i> , 2003, 3, 387-402.	7.7	429
64	p53 mutations and resistance to chemotherapy: A stab in the back for p73. <i>Cancer Cell</i> , 2003, 3, 303-305.	7.7	27
65	The p53 network in head and neck cancer. <i>Oral Oncology</i> , 2003, 39, 222-231.	0.8	119
66	Genetic influence on cigarette-induced cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2003, 45, 361-382.	1.6	13
67	Functional regulation of p73 and p63: development and cancer. <i>Trends in Biochemical Sciences</i> , 2003, 28, 663-670.	3.7	272
68	p73 and p63 protein stability: the way to regulate function?. <i>Biochemical Pharmacology</i> , 2003, 66, 1555-1561.	2.0	52
69	Contrasting selection pressures on components of the Ras-mediated signal transduction pathway in <i>Drosophila</i> . <i>Molecular Ecology</i> , 2003, 12, 1315-1323.	2.0	54
70	p53 Codon 72 Arg Homozygotes Are Associated with an Increased Risk of Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1510-1514.	0.3	45
71	P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 444-449.	1.2	26
72	Haplotype Structure of TP53 Locus in Indian Population and Possible Association with Head and Neck Cancer. <i>Annals of Human Genetics</i> , 2003, 67, 26-34.	0.3	17

#	ARTICLE	IF	CITATIONS
73	Glutathione S-Transferase GSTM1, GSTT1 and p53 Codon 72 Polymorphisms in Human Tumor Cells. <i>Human Cell</i> , 2003, 16, 241-251.	1.2	29
74	Mouse models with modified p53 sequences to study cancer and ageing. <i>Cell Death and Differentiation</i> , 2003, 10, 443-450.	5.0	18
75	p73 can suppress the proliferation of cells that express mutant p53. <i>Oncogene</i> , 2003, 22, 5481-5495.	2.6	25
76	Characterization of the p53 mutants ability to inhibit p73 ^{Δ2} transactivation using a yeast-based functional assay. <i>Oncogene</i> , 2003, 22, 5252-5260.	2.6	43
77	Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. <i>Oncogene</i> , 2003, 22, 5667-5676.	2.6	111
78	The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. <i>Nature Genetics</i> , 2003, 33, 357-365.	9.4	1,188
79	p53 family members and chemoresistance in cancer: what we know and what we need to know. <i>Drug Resistance Updates</i> , 2003, 6, 323-328.	6.5	43
80	P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. <i>Lung Cancer</i> , 2003, 40, 259-266.	0.9	36
81	Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. <i>Cancer Letters</i> , 2003, 193, 199-205.	3.2	42
82	Negative autoregulation of p73 and p53 by $\Delta 2$ p73 in regulating differentiation and survival of human neuroblastoma cells. <i>Cancer Letters</i> , 2003, 197, 105-109.	3.2	28
83	Induction of apoptosis by the p53-related p73 and partial inhibition by the baculovirus-encoded p35 in neuronal cells. <i>Molecular Brain Research</i> , 2003, 113, 1-12.	2.5	8
84	Radiochemotherapy in head and neck cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 291-296.	3.4	11
85	Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 14230-14236.	1.6	35
86	Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants. <i>Journal of Virology</i> , 2003, 77, 11588-11595.	1.5	41
87	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 10546-10555.	1.6	36
88	p73 Is Regulated by Phosphorylation at the G2/M Transition. <i>Journal of Biological Chemistry</i> , 2003, 278, 49196-49202.	1.6	37
89	New Leads Suggest a Clinically Relevant Genotype-Phenotype Relationship for the p53 Gene. <i>Journal of the National Cancer Institute</i> , 2003, 95, 926-927.	3.0	2
90	Cyclin-dependent Kinases Phosphorylate p73 at Threonine 86 in a Cell Cycle-dependent Manner and Negatively Regulate p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 27421-27431.	1.6	55

#	ARTICLE	IF	CITATIONS
91	Restoring p53-Dependent Tumor Suppression. <i>Cancer Biology and Therapy</i> , 2003, 2, 54-62.	1.5	35
92	c-Abl Tyrosine Kinase Selectively Regulates p73 Nuclear Matrix Association. <i>Journal of Biological Chemistry</i> , 2003, 278, 34475-34482.	1.6	43
93	TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. <i>Mutagenesis</i> , 2003, 18, 377-385.	1.0	124
94	Prognostic value of p53 molecular status in high-risk primary breast cancer. <i>Annals of Oncology</i> , 2003, 14, 704-708.	0.6	17
95	The p53 Homology Trap. <i>Cancer Biology and Therapy</i> , 2003, 2, 64-67.	1.5	19
96	p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. <i>Cell Cycle</i> , 2003, 2, 345-346.	1.3	34
97	Methods for screening tumors for p53 status and therapeutic exploitation. <i>Expert Review of Molecular Diagnostics</i> , 2003, 3, 289-301.	1.5	14
98	Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair. <i>Current Cancer Drug Targets</i> , 2003, 3, 21-29.	0.8	79
99	Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at Exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's Lymphoma in Japanese. <i>Leukemia and Lymphoma</i> , 2004, 45, 957-964.	0.6	47
100	Family Feud in Chemosensitivity: p73 and Mutant p53. <i>Cell Cycle</i> , 2004, 3, 317-321.	1.3	52
101	Polymorphisms in XPD and TP53 and mutation in human lung cancer. <i>Carcinogenesis</i> , 2004, 26, 597-604.	1.3	53
102	p53 Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement. <i>Heart</i> , 2004, 90, 1069-1070.	1.2	5
103	Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast. <i>Carcinogenesis</i> , 2004, 25, 2319-2323.	1.3	12
104	p53 Designer Genes for the Modern Mouse. <i>Cell Cycle</i> , 2004, 3, 736-739.	1.3	15
105	p73 and p63: Why Do We Still Need Them?. <i>Cell Cycle</i> , 2004, 3, 884-892.	1.3	52
106	Keep in the p53 Family in Good Shape. <i>Cell Cycle</i> , 2004, 3, 903-909.	1.3	22
107	The Role of p53 Codon 72 and Human Papilloma Virus Status of Cutaneous Squamous Cell Carcinoma in the Swedish Population. <i>Acta Dermato-Venereologica</i> , 2004, 84, 439-444.	0.6	6
108	The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. <i>Cell Death and Differentiation</i> , 2004, 11, 962-973.	5.0	84

#	ARTICLE	IF	CITATIONS
109	p73: regulator in cancer and neural development. <i>Cell Death and Differentiation</i> , 2004, 11, S17-S22.	5.0	20
110	Analysis of p73 expression pattern in acute myeloid leukemias: lack of β -N-p73 expression is a frequent feature of acute promyelocytic leukemia. <i>Leukemia</i> , 2004, 18, 1804-1809.	3.3	24
111	p73-alpha is capable of inducing scotin and ER stress. <i>Oncogene</i> , 2004, 23, 3721-3725.	2.6	52
112	Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. <i>Oncogene</i> , 2004, 23, 3328-3337.	2.6	234
113	TP73 alterations in cervical carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 116-121.	1.0	26
114	Implications of apoptosis regulators in tumorigenesis. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 367-387.	2.7	51
115	A Comparison Study of Gastric Cancer Risk in Patients with Duodenal and Gastric Ulcer: Roles of Gastric Mucosal Histology and p53 Codon 72 Polymorphism. <i>Digestive Diseases and Sciences</i> , 2004, 49, 254-259.	1.1	14
116	Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 55, 743-755.	1.5	15
117	Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance. <i>Drug Development Research</i> , 2004, 62, 254-272.	1.4	4
118	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. <i>Human Mutation</i> , 2004, 24, 21-34.	1.1	46
119	p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. <i>International Journal of Cancer</i> , 2004, 108, 196-199.	2.3	375
120	Microfluidic system for DNA sequence detection. <i>Chemical Engineering Journal</i> , 2004, 101, 157-161.	6.6	6
121	Sequence-selective DNA detection using multiple laminar streams: A novel microfluidic analysis method. <i>Lab on A Chip</i> , 2004, 4, 1.	3.1	31
122	Selective Loss of Codon 72 Proline p53 and Frequent Mutational Inactivation of the Retained Arginine Allele in Colorectal Cancer. <i>Neoplasia</i> , 2004, 6, 529-535.	2.3	43
123	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. <i>Cell</i> , 2004, 119, 847-860.	13.5	1,140
124	Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. <i>Cancer Letters</i> , 2004, 208, 75-79.	3.2	24
125	Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1233-1241.	1.9	58
126	No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells. <i>Anti-Cancer Drugs</i> , 2004, 15, 679-688.	0.7	4

#	ARTICLE	IF	CITATIONS
127	Single-Nucleotide Polymorphisms in the p53 Pathway. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 111-119.	2.0	6
128	Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. International Journal of Gynecological Cancer, 2005, 15, 952-963.	1.2	33
129	p73, a sophisticated p53 family member in the cancer world. Cancer Science, 2005, 96, 729-737.	1.7	118
130	p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. British Journal of Cancer, 2005, 92, 30-35.	2.9	31
131	The p53 pathway: positive and negative feedback loops. Oncogene, 2005, 24, 2899-2908.	2.6	2,056
132	TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detection and Prevention, 2005, 29, 501-508.	2.1	19
133	Expression of p53 in renal carcinoma cells is independent of pVHL. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 578, 23-32.	0.4	22
134	In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer, 2005, 5, 105.	1.1	20
135	Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern india. International Journal of Cancer, 2005, 117, 786-793.	2.3	31
136	Smoking-gene Interaction and Disease Development: Relevance to Pancreatic Cancer and Atherosclerosis. World Journal of Surgery, 2005, 29, 344-353.	0.8	25
137	Specific molecule localization in microchannel laminar flow and its application for non-immobilized-probe analysis. Analytical and Bioanalytical Chemistry, 2005, 382, 1477-1483.	1.9	4
138	TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis, 2005, 26, 1770-1773.	1.3	62
139	p53 Genotypes and Risk of Glioma and Meningioma. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2220-2223.	1.1	35
140	The Role of P53 and MDM2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma. Cancer Research, 2005, 65, 9582-9587.	0.4	169
141	The Role of p53 and p73 Genes in Tumor Formation. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 3, 103-117.	0.0	0
142	DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel. Biomarkers, 2005, 10, 188-202.	0.9	18
143	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. Clinical Cancer Research, 2005, 11, 8372-8383.	3.2	89
144	Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis, 2005, 26, 1829-1834.	1.3	25

#	ARTICLE	IF	CITATIONS
145	Transactivation-dependent and -independent Regulation of p73 Stability. <i>Journal of Biological Chemistry</i> , 2005, 280, 28203-28214.	1.6	20
146	Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs. <i>Clinical Cancer Research</i> , 2005, 11, 4348-4356.	3.2	57
147	The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2502-2509.	3.2	60
148	Small inhibitory RNA “a tool for credentialing candidate genes. <i>Pharmacogenomics</i> , 2005, 6, 281-292.	0.6	1
149	p53 Codon 72 Alleles Influence the Response to Anticancer Drugs in Cells from Aged People by Regulating the Cell Cycle Inhibitor p21WAF1. <i>Cell Cycle</i> , 2005, 4, 1264-1271.	1.3	50
150	A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect. <i>Cancer Research</i> , 2005, 65, 5481-5484.	0.4	179
151	25 Years of p53 Research. , 2005, , .		22
152	Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1403-1411.	1.3	127
153	Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. <i>Molecular Brain Research</i> , 2005, 137, 98-103.	2.5	40
154	p53 mutation heterogeneity in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 834-842.	1.0	232
155	P53 and Prognosis. <i>Cell</i> , 2005, 120, 7-10.	13.5	234
156	The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. <i>Cancer Letters</i> , 2005, 222, 57-65.	3.2	89
157	Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India*. <i>Chest</i> , 2005, 128, 3999-4007.	0.4	50
158	The Individual Cell Properties of Oral Squamous Cell Carcinoma and p53 Tumor Suppressor Gene Mutation. <i>Oral Science International</i> , 2005, 2, 104-117.	0.3	12
159	Association of p53 Codon 72 Polymorphism with Risk of Hypopharyngeal Squamous Cell Carcinoma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 99-104.	0.8	19
160	P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. <i>Molecular Cancer</i> , 2006, 5, 68.	7.9	7
161	Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. <i>Lung Cancer</i> , 2006, 52, 9-14.	0.9	45
162	Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. <i>Carcinogenesis</i> , 2006, 27, 766-771.	1.3	39

#	ARTICLE	IF	CITATIONS
164	Association of TP53 Mutation, p53 Overexpression, and p53 Codon 72 Polymorphism with Susceptibility to Apoptosis in Adult Patients with Diffuse Astrocytomas. <i>International Journal of Biological Markers</i> , 2006, 21, 50-57.	0.7	5
165	Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics. <i>Current Drug Targets</i> , 2006, 7, 387-395.	1.0	5
166	p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 347-351.	0.7	19
167	The role of p53 protein family in gastrointestinal malignancies. <i>Cell Death and Differentiation</i> , 2006, 13, 935-940.	5.0	26
168	Transcriptional regulation by p53: one protein, many possibilities. <i>Cell Death and Differentiation</i> , 2006, 13, 951-961.	5.0	439
169	Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. <i>Oncogene</i> , 2006, 25, 1216-1224.	2.6	65
170	Polymorphisms in the p53 pathway. <i>Oncogene</i> , 2006, 25, 1602-1611.	2.6	203
171	Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2006, 30, 1113-1118.	0.4	44
172	Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 521-528.	1.2	45
173	p53 codon 72 polymorphism in basal cell carcinoma of the skin. <i>Pathology and Oncology Research</i> , 2006, 12, 29-33.	0.9	19
174	Germline polymorphism of p53 codon 72 in gynecological cancer. <i>Gynecologic Oncology</i> , 2006, 100, 173-178.	0.6	38
175	Re: "œœs the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients." <i>Gynecologic Oncology</i> , 2006, 101, 371-372.	0.6	8
176	Comment on "œœGermline polymorphism of p53 codon 72 in ovarian cancer" by Ueda et al.. <i>Gynecologic Oncology</i> , 2006, 101, 372-373.	0.6	3
177	p53 family members in myogenic differentiation and rhabdomyosarcoma development. <i>Cancer Cell</i> , 2006, 10, 281-293.	7.7	108
178	The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2006, 594, 181-188.	0.4	16
179	Comparative analysis of cancer genes in the human and chimpanzee genomes. <i>BMC Genomics</i> , 2006, 7, 15.	1.2	94
180	Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. <i>International Journal of Cancer</i> , 2006, 118, 577-582.	2.3	37
181	Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2006, 119, 2851-2860.	2.3	25

#	ARTICLE	IF	CITATIONS
182	Cross-Talks in the p53 Family: p63 is an Anti-Apoptotic Target for p73 and p53 Gain of Function Mutants. <i>Cell Cycle</i> , 2006, 5, 1996-2004.	1.3	40
183	c-Abl-independent p73 stabilization during gemcitabine- or 2-thio-2-d-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 400-410.	1.9	22
184	Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the p53 PIN3 A2-Pro72 Haplotype. <i>Digestion</i> , 2006, 74, 228-235.	1.2	19
185	Requirement of clathrin heavy chain for p53-mediated transcription. <i>Genes and Development</i> , 2006, 20, 1087-1099.	2.7	63
186	Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. <i>Journal of Clinical Pathology</i> , 2006, 60, 1040-1047.	1.0	40
187	Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function*. <i>Journal of Biological Chemistry</i> , 2006, 281, 34096-34103.	1.6	94
188	Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. <i>Journal of Experimental Medicine</i> , 2007, 204, 1295-1301.	4.2	111
189	The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. <i>British Journal of Cancer</i> , 2007, 96, 1302-1308.	2.9	23
190	Mig-6, Signal Transduction, Stress Response and Cancer. <i>Cell Cycle</i> , 2007, 6, 507-513.	1.3	90
192	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. <i>Carcinogenesis</i> , 2007, 28, 289-298.	1.3	115
193	Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2077-2081.	1.1	21
194	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		13
195	P73, P63 and Mutant P53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		3
196	Polymorphic TP53BP1 and TP53 Gene Interactions Associated with Risk of Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2007, 13, 4300-4305.	3.2	25
197	p73: A chiaroscuro gene in cancer. <i>European Journal of Cancer</i> , 2007, 43, 1361-1372.	1.3	37
198	The oncogenic roles of p53 mutants in mouse models. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 66-70.	1.5	79
199	The changing face of p53 in head and neck cancer. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2007, 36, 1123-1138.	0.7	38
200	Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53. <i>Nucleic Acids Research</i> , 2007, 35, 2093-2104.	6.5	123

#	ARTICLE	IF	CITATIONS
201	Microfluidic Thermodynamics of the Shift in Thermal Stability of DNA Duplex in a Microchannel Laminar Flow. <i>Journal of Physical Chemistry B</i> , 2007, 111, 6127-6133.	1.2	7
202	TP53: A master gene in normal and tumor suppression. , 0, , 233-244.		0
203	Mutant p53 proteins: Between loss and gain of function. <i>Head and Neck</i> , 2007, 29, 488-496.	0.9	45
204	The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models. <i>Oncogene</i> , 2007, 26, 2964-2974.	2.6	10
205	p53 alterations in human cancer: more questions than answers. <i>Oncogene</i> , 2007, 26, 2145-2156.	2.6	210
206	Reactivation of mutant p53: molecular mechanisms and therapeutic potential. <i>Oncogene</i> , 2007, 26, 2243-2254.	2.6	189
207	Mutant p53: an oncogenic transcription factor. <i>Oncogene</i> , 2007, 26, 2212-2219.	2.6	241
208	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. <i>Oncogene</i> , 2007, 26, 2157-2165.	2.6	796
209	Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. <i>Oncogene</i> , 2007, 26, 2220-2225.	2.6	158
210	p63 and p73 in human cancer: defining the network. <i>Oncogene</i> , 2007, 26, 5169-5183.	2.6	231
211	Versatile functions of p53 protein in multicellular organisms. <i>Biochemistry (Moscow)</i> , 2007, 72, 1399-1421.	0.7	62
212	The association of the TP53 polymorphisms Pro72Arg and C(→594)CC with diabetic polyneuropathy in Russian Muscovites with type 1 diabetes mellitus. <i>Molecular Biology</i> , 2007, 41, 901-905.	0.4	9
213	p73 cooperates with Ras in the activation of MAP kinase signaling cascade. <i>Cell Death and Differentiation</i> , 2007, 14, 254-265.	5.0	22
214	Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. <i>Tissue Antigens</i> , 2007, 70, 283-293.	1.0	21
215	p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. <i>British Journal of Dermatology</i> , 2007, 156, 357-362.	1.4	27
216	Analysis of histopathological and immunohistochemical differences of oral squamous cell carcinoma in young and old patients in Sri Lanka. <i>Journal of Oral Pathology and Medicine</i> , 2007, 36, 357-362.	1.4	31
217	Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm. <i>Cancer Cell</i> , 2007, 12, 303-312.	7.7	316
218	p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007, 619, 38-44.	0.4	24

#	ARTICLE	IF	CITATIONS
219	TP53 codon 72 polymorphism in 12 populations of insular Southeast Asia and Oceania. <i>Journal of Human Genetics</i> , 2007, 52, 694-697.	1.1	8
220	Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008, 113, 799-807.	2.0	67
221	Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. <i>International Journal of Cancer</i> , 2008, 122, 2761-2766.	2.3	12
222	Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. <i>International Journal of Cancer</i> , 2008, 123, 577-585.	2.3	20
223	Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. <i>Journal of Zhejiang University: Science B</i> , 2008, 9, 847-852.	1.3	9
224	Germline polymorphism of cancer susceptibility genes in gynecologic cancer. <i>Human Cell</i> , 2008, 21, 95-104.	1.2	17
225	p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. <i>EMBO Journal</i> , 2008, 27, 792-803.	3.5	48
226	The dark side of a tumor suppressor: anti-apoptotic p53. <i>Cell Death and Differentiation</i> , 2008, 15, 959-976.	5.0	175
227	Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. <i>Oncogene</i> , 2008, 27, 2788-2794.	2.6	39
228	The p53 family and programmed cell death. <i>Oncogene</i> , 2008, 27, 6507-6521.	2.6	262
229	The genetics of the p53 pathway, apoptosis and cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 979-987.	21.5	568
230	p53 Arg72Pro Polymorphism Predicts Survival Outcome in Lung Cancer Patients in Indian Population. <i>Cancer Investigation</i> , 2008, 26, 41-46.	0.6	33
231	MDM2 SNP 309 and codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. <i>Radiotherapy and Oncology</i> , 2008, 87, 243-252.	0.3	52
232	Defect in Ser46 Phosphorylation of p53 Protein : A Resistance Mechanism against p53 Gene Transfer in Oral Squamous Cell Carcinoma Cells. <i>Journal of Oral Biosciences</i> , 2008, 50, 98-106.	0.8	2
233	p53: A new player in reproduction. <i>Cell Cycle</i> , 2008, 7, 848-852.	1.3	80
234	In good times and bad: p73 in cancer. <i>Cell Cycle</i> , 2008, 7, 1726-1731.	1.3	39
235	The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. <i>Cell Cycle</i> , 2008, 7, 3440-3447.	1.3	83
236	Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer. <i>Tumor Biology</i> , 2008, 29, 145-151.	0.8	19

#	ARTICLE	IF	CITATIONS
237	Possible Difference in Frequencies of Genetic Polymorphisms of Estrogen Receptor \hat{A} , Estrogen Metabolism and P53 Genes Between Estrogen Receptor-positive and -negative Breast Cancers. Japanese Journal of Clinical Oncology, 2008, 38, 734-742.	0.6	18
238	Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Current Genomics, 2008, 9, 200-207.	0.7	20
239	p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis, 2008, 29, 875-879.	1.3	43
240	The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle, 2008, 7, 158-163.	1.3	80
241	Restoration of p53 to limit tumor growth. Current Opinion in Oncology, 2008, 20, 90-96.	1.1	96
242	Significance of genetic instability in development and chemosensitivity of malignant tumors. Orvosi Hetilap, 2009, 3, 175-185.	0.2	0
243	Impact of Interaction of Polymorphic Forms of <i>p53</i> Codon 72 and <i>N-Acetylation</i> Gene (<i>NAT2</i>) on the Risk of Lung Cancer in the North Indian Population. DNA and Cell Biology, 2009, 28, 443-449.	0.9	19
244	Prognostic Significance of <i>p53</i> Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma. Clinical Cancer Research, 2009, 15, 2406-2416.	3.2	83
245	Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncology Reports, 2009, 22, 1205-11.	1.2	20
246	One billion years of p53/p63/p73 evolution. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17609-17610.	3.3	63
247	Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. Oral Oncology, 2009, 45, 683-686.	0.8	6
248	Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. Mechanisms of Ageing and Development, 2009, 130, 122-127.	2.2	12
249	Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer, 2009, 9, 420.	1.1	18
250	Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecologic Oncology, 2009, 113, 109-114.	0.6	41
251	Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. Journal of Cellular and Molecular Medicine, 2009, 13, 440-453.	1.6	60
252	<i>TP53</i> Arg72Pro polymorphism and lung cancer risk: A meta-analysis. International Journal of Cancer, 2009, 125, 2903-2911.	2.3	30
253	Combination of <i>p53</i> codon 72 polymorphism and inactive <i>p53</i> mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. International Journal of Cancer, 2010, 126, 1691-1701.	2.3	19
254	Polymorphisms at <i>p53</i> , <i>p73</i> , and <i>MDM2</i> loci modulate the risk of tobacco associated leukoplakia and oral cancer. Molecular Carcinogenesis, 2009, 48, 790-800.	1.3	52

#	ARTICLE	IF	CITATIONS
255	The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 336-347.	2.2	49
256	A role for the p53 pathway in the pathology of meningiomas with NF2 loss. Journal of Neuro-Oncology, 2009, 91, 265-270.	1.4	21
257	Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Research and Treatment, 2009, 118, 15-20.	1.1	8
258	Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Pathology and Oncology Research, 2009, 15, 359-368.	0.9	34
259	Association of <i>TP53</i> and <i>MDM2</i> polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Science, 2009, 100, 2376-2382.	1.7	23
260	p53 polymorphisms: cancer implications. Nature Reviews Cancer, 2009, 9, 95-107.	12.8	564
261	Mutant p53 mediates survival of breast cancer cells. British Journal of Cancer, 2009, 101, 1606-1612.	2.9	148
262	Common Polymorphisms in the <i>MDM2</i> and <i>TP53</i> Genes and the Relationship between <i>TP53</i> Mutations and Patient Outcomes in Glioblastomas. Brain Pathology, 2009, 19, 188-194.	2.1	37
263	Association of p53 polymorphisms and colorectal cancer: Modulation of risk and progression. European Journal of Surgical Oncology, 2009, 35, 415-419.	0.5	25
264	TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncology, The, 2009, 10, 772-784.	5.1	133
265	R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History. Pathology and Oncology Research, 2010, 16, 563-568.	0.9	11
266	Germline polymorphisms of glutathione-S-transferase GSTM1, GSTT1 and p53 codon 72 in cervical carcinogenesis. Human Cell, 2010, 23, 119-125.	1.2	12
267	Association of P53 codon 72 polymorphism and ameloblastoma. Oral Diseases, 2010, 16, 631-635.	1.5	14
268	Linking environmental carcinogen exposure to <i>TP53</i> mutations in human tumours using the human <i>TP53</i> knock-in (Hupki) mouse model. FEBS Journal, 2010, 277, 2567-2583.	2.2	57
269	Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 1-13.	0.8	18
270	TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genetics and Molecular Research, 2010, 9, 651-660.	0.3	41
271	Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncology Reports, 2010, 23, 1361-8.	1.2	18
272	p53 as the main traffic controller of the cell signaling network. Frontiers in Bioscience - Landmark, 2010, 15, 1172.	3.0	12

#	ARTICLE	IF	CITATIONS
273	Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. <i>Carcinogenesis</i> , 2010, 31, 1475-1482.	1.3	55
274	p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach?. <i>Cell Cycle</i> , 2010, 9, 720-728.	1.3	60
275	Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat. <i>Current Drug Targets</i> , 2010, 11, 667-681.	1.0	16
276	p53 family: therapeutic targets in neuroblastoma. <i>Future Oncology</i> , 2010, 6, 429-444.	1.1	18
277	Mouse Models for the p53 R72P Polymorphism Mimic Human Phenotypes. <i>Cancer Research</i> , 2010, 70, 5851-5859.	0.4	49
278	Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 263-268.	1.0	20
279	Single-nucleotide Polymorphisms in the p53 Signaling Pathway. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001032-a001032.	2.3	90
280	Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2010, 36, 431-438.	0.5	25
281	The role of genetic variants in human longevity. <i>Ageing Research Reviews</i> , 2010, 9, S67-S78.	5.0	43
282	Mutant p53 Gain-of-Function in Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001107-a001107.	2.3	621
283	p53 Arg72Pro Polymorphism and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1840-1847.	1.1	41
284	TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001008-a001008.	2.3	1,494
286	TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73. <i>Molecular and Cellular Biology</i> , 2011, 31, 4464-4481.	1.1	99
287	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. <i>Advances in Cancer Research</i> , 2011, 110, 107-139.	1.9	61
288	Coordination of TP53 Abnormalities in Breast Cancer: Data from Analysis of TP53 Polymorphisms, Loss of Heterozygosity, Methylation, and Mutations. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 901-907.	0.3	6
289	LQTS-associated mutation A257G in β 1-syntrophin interacts with the intragenic variant P74L to modify its biophysical phenotype. <i>Neurology International</i> , 2011, 1, 13.	0.2	9
290	Tumour suppressor gene p53 mutations in atypical vascular lesions of breast skin following radiotherapy. <i>Histopathology</i> , 2011, 58, 455-466.	1.6	24
291	Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. <i>Oncogene</i> , 2011, 30, 3612-3624.	2.6	21

#	ARTICLE	IF	CITATIONS
292	TP53 Arg72Pro Polymorphism and Skin Cancer Risk: A Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 220-228.	0.3	37
293	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2011, 38, 215-224.	0.8	21
294	The role of mutant p53 in human cancer. <i>Journal of Pathology</i> , 2011, 223, 116-126.	2.1	324
295	Arg72Pro <i>TP53</i> polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. <i>International Journal of Cancer</i> , 2011, 129, 920-930.	2.3	61
296	p73 in Cancer. <i>Genes and Cancer</i> , 2011, 2, 491-502.	0.6	124
297	Targeting p73 - a Potential Approach in Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2011, 17, 591-602.	0.9	10
298	The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. <i>Carcinogenesis</i> , 2011, 32, 327-330.	1.3	23
299	Functional <i>EGFR</i> Germline Polymorphisms May Confer Risk for <i>EGFR</i> Somatic Mutations in Non-Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. <i>Cancer Research</i> , 2011, 71, 2423-2427.	0.4	44
300	Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. <i>Cancer Biology and Therapy</i> , 2011, 11, 740-745.	1.5	38
301	p73 as a Pharmaceutical Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 578-590.	0.9	33
302	Association Between XRCC1 ARG399GLN and P53 ARG72PRO Polymorphisms and the Risk of Gastric and Colorectal Cancer in Turkish Population. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2011, 62, 207-214.	0.4	31
303	The Arg72Pro Polymorphism of TP53 in Croatian Population. <i>Croatica Chemica Acta</i> , 2012, 85, 239-243.	0.1	4
304	Investigation of the Effect of MDM2 SNP309 and TP53 Arg72Pro Polymorphisms on the Age of Onset of Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1471-1478.	0.3	11
305	Genetic modifiers of Huntington's disease: beyond CAG. <i>Future Neurology</i> , 2012, 7, 93-109.	0.9	20
306	Mutant p53 cooperates with ETS2 to promote etoposide resistance. <i>Genes and Development</i> , 2012, 26, 830-845.	2.7	164
307	Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. <i>Mutagenesis</i> , 2012, 27, 211-218.	1.0	105
308	Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis. <i>Journal of Biomedical Research</i> , 2012, 25, 25-32.	0.7	4
309	Impact of codon 72 Arg>Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. <i>Tumor Biology</i> , 2012, 33, 927-933.	0.8	10

#	ARTICLE	IF	CITATIONS
310	Mutant p53: one name, many proteins. <i>Genes and Development</i> , 2012, 26, 1268-1286.	2.7	998
311	Chronic low dose UV exposure and p53 mutation: Tilting the odds in early epidermal preneoplasia?. <i>International Journal of Radiation Biology</i> , 2012, 88, 682-687.	1.0	10
312	Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas. <i>PLoS ONE</i> , 2012, 7, e34422.	1.1	15
313	Therapeutic Targeting of p53-Mediated Apoptosis Pathway in Head and Neck Squamous Cell Carcinomas: Current Progress and Challenges. , 0, , .		2
314	Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma. <i>Genetics and Molecular Research</i> , 2012, 11, 3618-3628.	0.3	3
315	TP53 Gene Polymorphisms in Cancer Risk: The Modulating Effect of Ageing, Ethnicity and TP53 Somatic Abnormalities. , 0, , .		0
316	Chromosome instability and deregulated proliferation: an unavoidable duo. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2009-2024.	2.4	36
317	Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. <i>Histopathology</i> , 2012, 61, 247-256.	1.6	20
318	MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 602-607.	0.8	9
319	Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. <i>Molecular Biology Reports</i> , 2012, 39, 1731-1738.	1.0	12
320	<i>EGFR</i> exon 19 inâ€frame deletion and polymorphisms of DNA repair genes in neverâ€smoking female lung adenocarcinoma patients. <i>International Journal of Cancer</i> , 2013, 132, 449-458.	2.3	12
321	Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2013, 8, 117.	1.2	10
322	Colorectal cancer: a researcherâ€™s perspective of the molecular angelâ€™s gone eccentric in the Vale of Kashmir. <i>Tumor Biology</i> , 2013, 34, 1301-1315.	0.8	15
323	Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. <i>Cancer Cell International</i> , 2013, 13, 33.	1.8	13
324	TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 621-625.	0.8	12
326	p53 in the Clinics. , 2013, , .		1
327	Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 611-619.	1.1	7
328	Genotype Misclassification in Genetic Association Studies of the rs1042522 TP53 (Arg72Pro) Polymorphism: A Systematic Review of Studies of Breast, Lung, Colorectal, Ovarian, and Endometrial Cancer. <i>American Journal of Epidemiology</i> , 2013, 177, 1317-1325.	1.6	48

#	ARTICLE	IF	CITATIONS
329	Correlation of <i>TP53</i> and <i>MDM2</i> genotypes with response to therapy in sarcoma. <i>Cancer</i> , 2013, 119, 1013-1022.	2.0	36
330	HPV Has Left the Building—the Absence of Detectable HPV DNA and the Presence of R Allele/S for the P72R Polymorphism in the TP53 Gene May Call for More Aggressive Therapeutic Approach in HPV-Associated Tumours. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4217-4221.	0.5	1
331	Polymorphism <i>Arg72Pro</i> of <i>p53</i> Confers Susceptibility to Squamous Cell Carcinoma of Lungs in a North Indian Population. <i>DNA and Cell Biology</i> , 2013, 32, 66-72.	0.9	5
332	TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers. , 2013, , 127-146.		2
333	p53 codon 72 polymorphism in Taiwanese breast cancer patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 259-264.	0.8	12
334	YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. , 2013, , 147-172.		3
335	Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. <i>Cell Death and Differentiation</i> , 2013, 20, 898-909.	5.0	215
336	Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. <i>Cancer</i> , 2013, 119, 1106-1112.	2.0	16
337	Targeting p73 in cancer. <i>Cancer Letters</i> , 2013, 332, 229-236.	3.2	34
338	Association of TP53 codon 72 polymorphism with susceptibility to ovarian carcinomas in Serbian women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 166, 90-93.	0.5	7
339	The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 19257-19275.	1.8	78
340	Colorectal Cancer: Molecular Mutations and Polymorphisms. <i>Frontiers in Oncology</i> , 2013, 3, 114.	1.3	121
341	Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 793-804.	2.8	40
342	Meta-Analysis Reveals a Lack of Association between UGT2B17 Deletion Polymorphism and Tumor Susceptibility. <i>PLoS ONE</i> , 2014, 9, e96812.	1.1	4
343	P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2014, 19, e550-e555.	0.7	12
344	Battle Against Cancer: An Everlasting Saga of p53. <i>International Journal of Molecular Sciences</i> , 2014, 15, 22109-22127.	1.8	25
345	Tumor Suppressor p53 Alters Host Cell Metabolism to Limit <i>Chlamydia trachomatis</i> Infection. <i>Cell Reports</i> , 2014, 9, 918-929.	2.9	92
346	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2

#	ARTICLE	IF	CITATIONS
347	Marine Compounds. , 2014, , 209-250.		0
348	â€œP53 Codon 72 Single Base Substitution in Viral Hepatitis C and Hepatocarcinoma Incidencesâ€• Indian Journal of Clinical Biochemistry, 2014, 29, 3-7.	0.9	4
349	Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, e146-e150.	0.2	19
350	<i>TP63</i> and <i>TP73</i> in cancer, an unresolved â€œfamilyâ€•puzzle of complexity, redundancy and hierarchy. FEBS Letters, 2014, 588, 2590-2599.	1.3	39
351	Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma. Oncology Reports, 2014, 31, 223-231.	1.2	10
352	Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis. Oncology Reports, 2014, 31, 1396-1406.	1.2	6
353	Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells. BMC Genomics, 2015, 16, 654.	1.2	10
354	Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer. Cancer Biomarkers, 2015, 15, 459-465.	0.8	15
355	Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis. Melanoma Research, 2015, 25, 453-460.	0.6	36
356	Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Frontiers in Oncology, 2015, 5, 249.	1.3	80
357	Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population. Oncology Letters, 2015, 10, 3216-3222.	0.8	5
358	Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: A review of the current literature. Gynecologic Oncology, 2015, 136, 143-157.	0.6	85
359	Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2443-2448.	3.3	59
360	Molecular biomarkers in colorectal carcinoma. Pharmacogenomics, 2015, 16, 1189-1222.	0.6	14
361	Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of <i>TMC/EVER</i> Alterations. Dermatology, 2015, 231, 245-252.	0.9	3
362	Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nature Communications, 2015, 6, 7389.	5.8	104
363	Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses. Tumor Biology, 2015, 36, 9259-9265.	0.8	10
364	Different patterns of allelic imbalance in sporadic tumors and tumors associated with long-term exposure to gamma-radiation. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2015, 794, 8-16.	0.9	0

#	ARTICLE	IF	CITATIONS
365	A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. <i>Oncogene</i> , 2015, 34, 1094-1104.	2.6	66
366	Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. <i>Frontiers in Oncology</i> , 2016, 6, 12.	1.3	49
367	Oncogenic Intra-p53 Family Member Interactions in Human Cancers. <i>Frontiers in Oncology</i> , 2016, 6, 77.	1.3	59
368	Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years™ Follow-Up. <i>International Journal of Biological Markers</i> , 2016, 31, 183-192.	0.7	7
369	Evaluation of the antineoplastic activity of gallic acid in oral squamous cell carcinoma under hypoxic conditions. <i>Anti-Cancer Drugs</i> , 2016, 27, 407-416.	0.7	34
370	Genetic Modifiers of the p53 Pathway. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026302.	2.9	52
371	Somatic TP53 Mutations in the Era of Genome Sequencing. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026179.	2.9	176
372	Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission. <i>Journal of Cell Biology</i> , 2017, 216, 1071-1089.	2.3	102
373	Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 908-927.	4.0	35
374	p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis. <i>Cell Death and Disease</i> , 2017, 8, e2995-e2995.	2.7	22
375	Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026054.	2.9	94
376	Neovascularization and functional recovery after intracerebral hemorrhage is conditioned by the Tp53 Arg72Pro single-nucleotide polymorphism. <i>Cell Death and Differentiation</i> , 2017, 24, 144-154.	5.0	35
377	Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 961.	1.8	41
378	Association between TP53 gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1149-1154.	1.0	25
379	Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1 β . <i>Genes and Development</i> , 2018, 32, 230-243.	2.7	81
380	SNPing away at mutant p53 activities. <i>Genes and Development</i> , 2018, 32, 195-196.	2.7	5
381	Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients. <i>Head and Neck</i> , 2018, 40, 943-954.	0.9	21
382	Mutant p53 partners in crime. <i>Cell Death and Differentiation</i> , 2018, 25, 161-168.	5.0	216

#	ARTICLE	IF	CITATIONS
383	p73, like its p53 homolog, shows preference for inverted repeats forming cruciforms. <i>PLoS ONE</i> , 2018, 13, e0195835.	1.1	10
384	Complexes formed by mutant p53 and their roles in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 101-112.	1.0	14
385	How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. <i>Drug Resistance Updates</i> , 2018, 38, 27-43.	6.5	91
386	Lichen Sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. <i>International Journal of Biological Sciences</i> , 2019, 15, 1429-1439.	2.6	88
387	New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. <i>Cancer Letters</i> , 2019, 446, 90-102.	3.2	36
388	Common genetic variants in the TP53 pathway and their impact on cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 578-585.	1.5	38
389	TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1202-1215.	3.0	39
390	Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5999.	1.8	64
391	Bifunctional ligand design for modulating mutant p53 aggregation in cancer. <i>Chemical Science</i> , 2019, 10, 10802-10814.	3.7	30
392	Regulators of Oncogenic Mutant TP53 Gain of Function. <i>Cancers</i> , 2019, 11, 4.	1.7	79
393	<i>Chlamydia trachomatis</i> impairs host base excision repair by downregulating polymerase β . <i>Cellular Microbiology</i> , 2019, 21, e12986.	1.1	8
394	Intronic TP53 Polymorphisms Are Associated with Increased β 133TP53 Transcript, Immune Infiltration and Cancer Risk. <i>Cancers</i> , 2020, 12, 2472.	1.7	13
395	Oral squamous cell carcinoma of the tongue dorsum with multiple cancer-associated mutations in the TP53 gene. <i>Oral Oncology</i> , 2020, 109, 104774.	0.8	4
396	p53's Extended Reach: The Mutant p53 Secretome. <i>Biomolecules</i> , 2020, 10, 307.	1.8	35
397	Germline mutation of <i>MDM4</i> , a major p53 regulator, in a familial syndrome of defective telomere maintenance. <i>Science Advances</i> , 2020, 6, eaay3511.	4.7	25
398	Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. <i>Journal of Advanced Research</i> , 2020, 24, 149-157.	4.4	13
399	Effect of the p53 P72R Polymorphism on Mutant <i>TP53</i> Allele Selection in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1246-1257.	3.0	16
400	Central Nervous System Tissue Regeneration after Intracerebral Hemorrhage: The Next Frontier. <i>Cells</i> , 2021, 10, 2513.	1.8	15

#	ARTICLE	IF	CITATIONS
401	TP53 mutational hot spots for Li-Fraumeni syndrome in Asian populations. <i>Tropical Medicine and International Health</i> , 2021, 26, 1401-1410.	1.0	1
402	Analysis of p53 Gene Alterations in Cancer: A Critical View. , 2007, , 255-292.		5
403	Role of the p53 Family in Stabilizing the Genome and Preventing Polyploidization. <i>Advances in Experimental Medicine and Biology</i> , 2010, 676, 73-91.	0.8	22
404	Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. <i>FEBS Journal</i> , 2010, 277, 2567-2583.	2.2	42
405	A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. , 2003, 10, 430.		2
406	Studies of the Association of Arg72Pro of Tumor Suppressor Protein p53 with Type 2 Diabetes in a Combined Analysis of 55,521 Europeans. <i>PLoS ONE</i> , 2011, 6, e15813.	1.1	49
407	Evidence for an Epistatic Effect between TP53 R72P and MDM2 T309G SNPs in HIV Infection: A Cross-Sectional Study in Women from South Brazil. <i>PLoS ONE</i> , 2014, 9, e89489.	1.1	4
408	TP53 Pro72 Allele Is Enriched in Oral Tongue Cancer and Frequently Mutated in Esophageal Cancer in India. <i>PLoS ONE</i> , 2014, 9, e114002.	1.1	11
409	The p53Pro72Arg Polymorphism is Associated with Albuminuria among Aboriginal Australians. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 677-683.	3.0	20
410	TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. <i>Aging</i> , 2012, 4, 28-39.	1.4	23
411	Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. <i>Oncotarget</i> , 2017, 8, 35848-35862.	0.8	14
412	No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects. <i>Oncotarget</i> , 2017, 8, 112761-112769.	0.8	2
413	Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <i>Oncotarget</i> , 2018, 9, 16234-16247.	0.8	24
414	Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. <i>Current Gene Therapy</i> , 2020, 20, 127-141.	0.9	31
417	Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. <i>World Journal of Gastroenterology</i> , 2005, 11, 289.	1.4	34
418	A p53 genetic polymorphism of gastric cancer: Difference between early gastric cancer and advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 6536.	1.4	39
419	Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. <i>World Journal of Gastroenterology</i> , 2006, 12, 1426.	1.4	54
420	TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. <i>World Journal of Gastroenterology</i> , 2015, 21, 10358.	1.4	15

#	ARTICLE	IF	CITATIONS
421	The role of myoglobin in epithelial cancers: Insights from transcriptomics. <i>International Journal of Molecular Medicine</i> , 2020, 45, 385-400.	1.8	13
422	Relationship among tobacco habits, human papilloma virus (HPV) infection, p53 polymorphism/mutation and the risk of oral squamous cell carcinoma. <i>Journal of Oral and Maxillofacial Pathology</i> , 2014, 18, 211.	0.3	16
423	p63 and p73 in Tumor Suppression and Promotion. <i>Cancer Research and Treatment</i> , 2004, 36, 6.	1.3	8
424	P53 Codon 72 Gene Polymorphism and Risk of Oral Squamous Cell Carcinoma in South Indian Population: A Case-Control Study. <i>Journal of Cancer Science & Therapy</i> , 2012, 04, .	1.7	4
425	Association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult patients with diffuse astrocytomas. <i>International Journal of Biological Markers</i> , 2006, 21, 50-57.	0.7	6
426	TP53 Codon 72 Polymorphism and Risk of Acute Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 347-350.	0.5	21
427	PCR-RFLP genotyping analysis of TP53 Arg72Pro polymorphism and susceptibility to esophageal cancer in Pakistani population. <i>Gene Reports</i> , 2021, 25, 101406.	0.4	0
428	TP53 in Carcinogenesis and Cancer Prevention. <i>Handbook of Experimental Pharmacology</i> , 2003, , 57-81.	0.9	0
429	Genetische Grundlagen der Kanzerogenese. , 2004, , 75-145.		1
430	Biological basis of cancer predisposition. , 2004, , 11-20.		4
431	Defect in Ser46 Phosphorylation of p53 Protein: A Resistance Mechanism against p53 Gene Transfer in Oral Squamous Cell Carcinoma Cells. <i>Journal of Oral Biosciences</i> , 2008, 50, 98-106.	0.8	0
432	Genetische Grundlagen der Kanzerogenese. , 2010, , 67-127.		0
433	The Molecular Pathogenesis of Aflatoxin with Hepatitis B Virus-Infection in Hepatocellular Carcinoma. , 0, , .		0
434	p53, p63 and p73 Network in Breast Cancers. , 0, , .		1
435	Restoring p53 Function: Novel Anticancer Approaches for an Old Foe. , 2012, , 192-227.		0
436	TP53 is a Mutational Target in Non Small Cell Lung Cancer Patients and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, 04, .	0.3	0
437	TP53 Gene Polymorphism in Epithelial Ovarian Carcinoma Patients from North Indian Population and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility. <i>Journal of Genetic Syndromes & Gene Therapy</i> , 2013, 04, .	0.2	0
438	The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: A meta-analysis including 7,107 subjects. <i>Indian Journal of Dermatology</i> , 2013, 58, 175.	0.1	1

#	ARTICLE	IF	CITATIONS
439	Bringing p53 into the Clinic. <i>Journal of Cancer Science & Therapy</i> , 2014, 06, .	1.7	2
440	p53 in Head and Neck Cancer. , 2014, , 227-258.		0
441	Discrimination of Codon 72 p53 Polymorphisms using High Resolution Melting Curve Method. <i>Asian Journal of Biochemistry</i> , 2014, 9, 142-150.	0.5	0
444	Molecular docking of the Cardenolides of <i>Asclepias subulata</i> in the human p53 protein reveals an interaction in the cleft of the Y220C mutant. <i>Current Chemical Biology</i> , 2021, 15, .	0.2	0
446	The Oncogenic Activity of p53 Mutants. , 2005, , 199-223.		2
448	Targeting Rb inactivation in cancers by synthetic lethality. <i>American Journal of Cancer Research</i> , 2011, 1, 773-86.	1.4	12
449	TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses. <i>International Journal of Biomedical Science</i> , 2008, 4, 248-54.	0.5	11
451	Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3198-203.	0.5	11
452	Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. , 2016, 2016, .		0
453	Tumor modifier genes. , 2002, 4, 349-357.		2
454	The Association Between Arg72Pro C>G Polymorphism in the <i>p53</i> Gene and the Risk of Obesity. <i>Åstanbul Medical Journal</i> ., 2022, 23, 55-59.	0.1	0
455	Should mutant TP53 be targeted for cancer therapy?. <i>Cell Death and Differentiation</i> , 2022, 29, 911-920.	5.0	47
456	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		0
457	Analysis of p53 Gene Alterations in Cancer: A Critical View. , 2007, , 255-292.		0
458	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		0
460	p63 and p73: Roles in Development and Tumor Formation. <i>Molecular Cancer Research</i> , 2004, 2, 371-386.	1.5	401
461	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. <i>Nature Communications</i> , 2022, 13, 2800.	5.8	21
462	Epidemiological Evidence for Associations Between Genetic Variants and Osteosarcoma Susceptibility: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
463	Benign SNPs in the Coding Region of <i>TP53</i> : Finding the Needles in a Haystack of Pathogenic Variants. <i>Cancer Research</i> , 2022, 82, 3420-3431.	0.4	6
464	Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas. <i>Cancers</i> , 2022, 14, 3388.	1.7	5
465	p53 Codon 72 Polymorphic Variants, Loss of Allele-Specific Transcription, and Human Papilloma Virus 16 and/or 18 E6 Messenger RNA Expression in Squamous Cell Carcinomas of the Head and Neck. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1805-1809.	1.1	15
466	p73 isoforms meet evolution of metastasis. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 853-869.	2.7	6
467	Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
468	A comprehensive study of p53 protein. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1891-1937.	1.2	7
471	Role of Genetic Variations in Determining Treatment Outcome in Head and Neck Cancer. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 114-121.	3.0	1
472	Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment. <i>Cancers</i> , 2022, 14, 6212.	1.7	2
473	Genetic scores for predicting longevity in the Croatian oldest-old population. <i>PLoS ONE</i> , 2023, 18, e0279971.	1.1	3
475	Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	6
477	Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent. <i>Cell Death and Differentiation</i> , 0, , .	5.0	0